

Icosavax, Inc.
1616 Eastlake Avenue E., Suite 208
Seattle, WA 98102

July 26, 2021

VIA EDGAR

Mr. Alan Campbell
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549

**Re: Icosavax, Inc.
Registration Statement on Form S-1
File No. 333-257733**

Dear Mr. Campbell

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Icosavax, Inc. (the "**Company**"), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on July 28, 2021, or as soon as practicable thereafter.

Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.

Very truly yours,

ICOSAVAX, INC.

By: /s/ Adam Simpson

Adam Simpson
Chief Executive Director

cc:

Suzanne Hayes, *Securities and Exchange Commission*
Julie Sherman, *Securities and Exchange Commission*
Brian Casio, *Securities and Exchange Commission*
Thomas Russo, CFA, *Icosavax, Inc.*
Cheston J. Larson, *Latham & Watkins LLP*
Matthew T. Bush, *Latham & Watkins LLP*
Alaina P. Ellis, *Latham & Watkins LLP*